33469/33521 - Blastomyces qPCR (Lower respiratory) & Blastomyces qPCR (CSF)
Blastomyces infections are caused by inhalation of spores of the fungus Blastomyces dermatitidis or Blastomyces gilchristii. This infection primarily affects the lungs but can spread to other organs and the geographic distribution shows B. dermatitidis is more common in the central and eastern United States, while B. gilchristii has been identified in the western United States. However, Blastomyces infections are now detected across the United States and this is suspected due to climate change and the travel habits of people. Blastomycosis, histoplasmosis, and coccidioidomycosis are often underrecognized and frequently misdiagnosed fungal infections as they can clinically resemble bacterial and viral community-acquired pneumonia (CAP). The utility of PCR (using a BAL, sputum or CSF specimen) has brought on advances in the detection and therapeutic monitoring, leading to increased survival rates and increased quality of care.
ProcedureExtraction of fungal DNA from BAL, CSF, or sputum specimens followed by PCR amplification of targets using real-time PCR methods. An internal control is added to ensure that extraction was performed correctly and that the PCR reaction was not inhibited.
SpecificityAll specimens were positive for UIC, with CT values ≤35.
No signal was detected in the following off-target fungal, bacterial, and viral pathogens:
| Aspergillus fumigatus | Escherichia coli 11775 | Parainfluenza 4B VR-1377 |
| Adenovirus strain 24 | Enterococcus faecalis ATCC 35550 | Rhinovirus VR-1645 |
| Burkholderia cepacia 13945 | Haemophilus influenzae 8142 | RSV A VR-26 |
| Blastomyces parvus ATCC 10785 | Human Coronavirus ATCC 25238 | RSV B VR-1794 |
| Candida albicans ATCC 18804 | Influenza A H1N1 A/New Jersey/8/76 | Staphylococcus aureus 12600 |
| Candida auris MYA-5002 | Influenza B VR-295 | Staphylococcus epidermidis 35547 |
| Candida glabrata ATCC 66032 | Klebsiella pneumoniae 35555 | Serratia marcescens 264 |
| Candida krusei ATCC 6258 | Mycobacteroides abscessus | Streptococcus pneumoniae Z 022 |
| Candida parapsilosis ATCC 22019 | Moraxella catarrhalis ATCC 25238 | Streptococcus pyogenes ATCC BAA-947 |
| Candida tropicalis ATCC 750 | Mucor racemosus ATCC 42647 | SARS CoV-2 |
| Coxsackievirus B4 0810075CF | Pseudomonas aeruginosa 35422 | Swine Flu VR-1737 |
| Enterobacter cloacae ATCC 35549 | Paracoccidioides brasiliensis ATCC 10237 |
Same day (< 24 hours from receipt of specimen), Monday through Saturday.
| Specimen Type | Test Code | CPT Code | NY Approved | Volume | Assay Range | Special Instructions |
|---|---|---|---|---|---|---|
| Lower respiratory | 33469 | 87798 | No | 5 mL (min. 0.5 mL)* |
250 copies/mL to 1.25E+09 copies/mL |
• If reflex NGS testing is being considered, please submit at least 5.0 mL of BAL.* |
| CSF | 33521 | 87798 | No | 2 mL (min. 0.5 mL) |
250 copies/mL to 1.25E+09 copies/mL |
• Collect in a sterile, screw top tube. |
Ship Monday through Friday. Friday shipments must be labeled for Saturday delivery. All specimens must be labeled with patient's name and collection date. A Eurofins Viracor test requisition form must accompany each specimen. Multiple tests can be run on one specimen. Ship specimens FedEx Priority Overnight® to: Eurofins Viracor, 18000 W 99th St. Ste, #10, Lenexa, KS 66219.
Respiratory sample received in trap, specimen received outside stability, insufficient specimen volume and specimen types other than those listed.
Specimens are approved for testing in New York only when indicated in the Specimen Information field above. The CPT codes provided are based on Eurofins Viracor’s interpretation of the American Medical Association's Current Procedural Terminology (CPT) codes and are provided for informational purposes only. CPT coding is the sole responsibility of the billing party. Questions regarding coding should be addressed to your local Medicare carrier. Eurofins Viracor assumes no responsibility for billing errors due to reliance on the CPT codes illustrated in this material.
References1. Smith JA, Riddell J, Kauffman CA. Cutaneous manifestations of endemic mycoses. CurrInfect Dis Rep. 2013 Oct;15(5):440-9. [PubMed: 23917880]
2. Chapman SW, Lin AC, Hendricks KA, Nolan RL, Currier MM, Morris KR, Turner HR.Endemic blastomycosis in Mississippi: epidemiological and clinical studies. Semin RespirInfect. 1997 Sep;12(3):219-28. [PubMed: 9313293]
3. Gray NA, Baddour LM. Cutaneous inoculation blastomycosis. Clin Infect Dis. 2002 May15;34(10):E44-9. [PubMed: 11981746]
4. Saccente M, Woods GL. Clinical and laboratory update on blastomycosis. Clin MicrobiolRev. 2010 Apr;23(2):367-81. [PMC free article: PMC2863359] [PubMed: 20375357]
5. Castillo CG, Kauffman CA, Miceli MH. Blastomycosis. Infect Dis Clin North Am. 2016Mar;30(1):247-64. [PubMed: 26739607]6.
6. Lohrenz S, Minion J, Pandey M, Karunakaran K. Blastomycosis in Southern Saskatchewan2000-2015: Unique presentations and disease characteristics. Med Mycol. 2018 Oct01;56(7):787-795. [PubMed: 29924358]7.
7. Patel AJ, Gattuso P, Reddy VB. Diagnosis of blastomycosis in surgical pathology and cytopathology: correlation with microbiologic culture. Am J Surg Pathol. 2010Feb;34(2):256-61. [PubMed: 20090507]8.
8. Goughenour KD, Rappleye CA. Antifungal therapeutics for dimorphic fungal pathogens. Virulence. 2017 Feb 17;8(2):211-221. [PMC free article: PMC5354166] [PubMed:27646561]9.
9. Lestner J, Hope WW. Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections. Expert Opin Drug Metab Toxicol. 2013Jul;9(7):911-26. [PubMed: 23641752]10.
10. Baker T, Patel A, Halteh P, Toussi SS, DeLaMora P, Lipner S, Schuetz AN, Hartman B. Blastomycosis during pregnancy: a case report and review of the literature. Diagn Microbiol Infect Dis. 2017 Jun;88(2):145-151. [PubMed: 28291633]11.
11. Schwartz IS, Embil JM, Sharma A, Goulet S, Light RB. Management and Outcomes of Acute Respiratory Distress Syndrome Caused by Blastomycosis: A Retrospective Case
12. Series. Medicine (Baltimore). 2016 May;95(18):e3538. [PMC free article: PMC4863776][PubMed: 27149459]
13. Maubon, D., Simon, S., and Aznar, C. (2007). Histoplasmosis diagnosis using a polymerase chain reaction method. application on human samples in French Guiana, South America. Diagn.Microbiol. Infect. Dis. 58, 441–444. doi: 10.1016/j.diagmicrobio.2007.03.008
14. Molina-Morant, D., Sánchez-Montalvá, A., Salvador, F., Sao-Avilés, A., and Molina, I. (2018). Imported endemic mycoses in Spain: evolution of hospitalized cases, clinical characteristics and correlation with migratory movements, 1997-2014. PLoS Negl. Trop. Dis. 12:e0006245. doi: 10.1371/journal.pntd.0006245
15. Muraosa, Y., Toyotome, T., Yahiro, M., Watanabe, A., Shikanai-Yasuda, M. A., and Kamei, K. (2016). Detection of Histoplasma capsulatum from clinical specimens by cycling probe-based real-time PCR and nested real-time PCR. Med. Mycol. 54, 433–438. Doi: 10.1093/mmy/myv106